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Background: Angiotensinogen (AGT) constitutes a central component of the renin-angiotensin system that
controls the systemic blood pressure and several other cardiovascular functions and may play an important role in
atherosclerosis pathways. In this study, we employed TaqMan genotyping assays to evaluate the role of 8 AGT
variants in primary hypertension (HTN), type 2 diabetes mellitus (T2DM), and obesity as a possible trigger of
coronary artery disease (CAD) in a population of 4615 angiographed native Saudi individuals.
Methods: Linkage analysis was done by using the Affymetrix Gene Chip array, sequencing by using the MegaBACE
DNA analysis system and genotyping accomplished by TaqMan chemistry using the Applied Biosystem real-time
Prism 7900HT Sequence Detection System.
Results: Six variants, rs2067853 GG [Odds ratio(95% Confidence Interval) = 1.44(1.17-1.78); p = 0.001], rs7079 [1.49
(1.20-1.85); p < 0.0001], rs699 G [1.19(1.08-1.13); p < 0.0001], rs3789679 A [1.51(1.14-1.99); p = 0.004], rs2148582 GG
[1.31(1.11-1.55); p = 0.002] and rs5051 TC + CC [1.32(1.13-1.60); p = 0.001] conferred risk for HTN (3521 cases versus
1094 controls). The rs2067853 (p = 0.042), rs699G (p = 0.007) and rs5051 (p = 0.051) also conferred risk for myocardial
infarction (MI; 2982 vs 1633), while rs3789679 A (p < 0.0001) and GA + AA (p < 0.0001) as well as rs4762G (p = 0.019)
were associated with obesity (1576 vs 2458). However, while these variants appeared to be also associated with
CAD (2323 vs 2292), only the rs7079G (p = 0.035) retained its significant relationship. Interestingly, among the
haplotypes constructed from these SNPs, the baseline 8-mer haplotype, GGTGGGGT (χ2 = 7.02; p = 0.0081) and
another GGCGGAGT (χ2 = 5.10; p = 0.024), together with several of their derivatives were associated with HTN. T2DM
was associated with two 8-mer haplotypes, GGTAGGAC (χ2 = 5.66; p = 0.017) and ATTGAGAC (χ2 = 5.93; p = 0.015),
obesity with GGCGGAGT (χ2 = 9.49; p = 0.0021) and MI was linked to ATTGGGAC (χ2 = 6.68; p = 0.010) and
GGTGGGAT (χ2 = 4.25; p = 0.039). Furthermore, several causative haplotypes were also shared among the risk traits
as well as with CAD.
Conclusion: These results point to AGT as independently conferring risk for various cardiovascular traits, and
possibly interacting with these traits in events leading to atherosclerosis.
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The renin-angiotensin-aldosterone system (RAAS) is the
core regulator of systemic blood pressure. An essential
component of this system is angiotensinogen (AGT), a
serum renin glycoprotein substrate synthesized and re-
leased in the liver as the precursor of angiotensin, the
hormone that constitutes part of the systemic blood
pressure control system [1]. By virtue of the function of
AGT in regulating blood pressure, changes in its gene
sequence are likely to play an important role in the
pathogenesis of cardiovascular risk traits, such as hyper-
tension, as well as manifestation of coronary artery dis-
ease (CAD) [2,3]. Several AGT variants, including the
rs4762 (p.M207T, also formerly known as p.T174M) and
rs699 (p.M268T, also referred to as p.M235T), have been
associated with susceptibility to various cardiovascular
risk traits, such as primary hypertension (HTN) [4-10]
and type 2 diabetes (T2DM) [11,12], that are linked to
the development of CAD. These variants have similarly
been implicated not only in the manifestation of CAD
[13-23], but also in the severity of atherosclerosis
[24,25]. The fact that the AGT gene constitutes a risk for
these disease traits as well as CAD strongly implicates
gene-disease interactions in pathways that trigger ath-
erosclerosis, a subject that has attracted considerable re-
search interest recently. Indeed, a number of studies
have indicated that such gene-trait or gene-gene interac-
tions contribute to events leading to complex disorders,
such as CAD [5,26-31]. However, this subject has not
been exhaustively addressed yet. Besides, the notion of
some of the AGT variants or their interactions with such
disease risk traits playing a role in CAD/myocardial in-
farction (MI) has been refuted by a number of studies in
various ethnic groups [21,22]. We recently described as-
sociations of several AGT variants with CAD in hetero-
zygous familial hypercholesterolaemia through linkage
and population-based association studies in a large,
angiographed and ethnically homogeneous Saudi cohort
[9]. In the present study, we specifically asked the ques-
tion whether alterations in the AGT gene are a common
cause for different cardiovascular risk factors, thereby
posing an additional risk to acquiring CAD in individ-
uals harbouring such risk traits. We employed the same




The initial linkage study was performed in a Saudi family
of eleven with heterozygous familial hypercholesterol-
aemia, in which the primary proband underwent triple
bypass surgery at the age of 14 years (Additional file 1:
Family Suppl data). This was followed by a case–control
study in a total of 4615 native Saudi individuals from allfive regions of the country, comprising 850 (18.4%) from
the Eastern, 1008 (21.8%) from the Central, 1207(26.2%)
from the Northern, 1184 (25.7%) from the Southern and
366 (7.7%) from the Western Region. This population
consisted of 2323 CAD patients (1777 males and 546 fe-
males, mean age 60.2 ± 0.2 yr) with angiographically de-
termined narrowing of the coronary vessels by at least
50% and 2292 angiographed controls (1245 male and
1047 female, mean age 50.6 ± 0.4 yr). Among these, 3521
individuals had primary (essential) hypertension (HTN)
(Table 1), defined as ≥140 mm Hg systolic blood pres-
sure or ≥90 mm Hg diastolic pressure based on The
Sixth Report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC VI) criteria [32]. Accordingly, es-
sential, primary or idiopathic hypertension is defined as
high blood pressure (HBP) in which secondary causes
such as renovascular disease, renal failure, pheochromo-
cytoma, aldosteronism, or other causes of secondary
hypertension or Mendelian forms (monogenic) are not
present [32]. The third subset of interest comprised
2544 individuals with T2DM (formerly known as non-
insulin-dependent diabetes mellitus or adult onset dia-
betes). The National Diabetes Data Group of the USA
and the second World Health Organization Expert
Committee on Diabetes Mellitus (1998) [33] define type
2 diabetes mellitus as a metabolic disorder that is char-
acterized by high blood glucose (generally described as
fasting glucose level >126 mg/dL) in the context of insu-
lin resistance and its relative deficiency. The fourth
group constituted 1576 obese patients with body-mass
index of ≥30.0 kg/m2, and classified as the obesity sub-
set. Furthermore, 2982 individuals had established MI.
Among these subsets of patients, some individuals
harboured a combination of two or possibly three of the
cardiovascular risk traits. The overall exclusion criteria
for the disease cases were major cardiac rhythm distur-
bances, incapacitating or life-threatening illness, major
psychiatric illness or substance abuse, history of cerebral
vascular disease, neurological disorder, and administra-
tion of psychotropic medication. The controls (CON)
for CAD were a group of individuals undergoing surgery
for heart valvular diseases, and those who may have
reported with chest pain, but were established to have
no significant coronary stenosis by angiography. All pa-
tients included in study were undergoing their standard
prescribed treatments for their respective ailments at
our Institution. These included Zocor Pravastatin and
Lipostat for hyperlipidaemia as well as Renitec, Hyzaar,
Capoten, atenolol, metoprolol and carvedil for hyperten-
sion. Exclusion criteria for this group were among others
diseases such as cancer, autoimmune disease, or any
other disorders likely to interfere with variables under
investigation. This study was performed in accordance
Table 1 Important clinical features and demographics of the studied individuals
Controls Cases
All Male Female All Male Female
CAD 2292 1245(0.54) 1047(0.46) 2323 1777(0.76) 546(0.24)
MI 853 558(0.65) 295(0.35) 2180 1682(0.77) 498(0.23)
T2DM 954 524(0.55) 430(0.45) 1589 1175(0.74) 414(0.26)
HTN 1559 828(0.53) 731(0.47) 1962 1474(0.75) 488(0.25)
hChol 593 312(0.53) 281(0.47) 1078 796(0.74) 282(0.26)
lHDL 729 487(0.67) 242(0.33) 1181 979(0.83) 202(0.17)
hTG 427 267(0.63) 160(0.37) 728 554(0.76) 174(0.24)
hLDL 886 456(0.51) 430(0.49) 965 717(0.74) 248(0.26)
FH 542 299(0.55) 243(0.45) 359 287(0.80) 72(0.20)
OBS 888 385((0.43) 503(0.57) 857 573(0.67) 284(0.33)
Smokers 685 639(0.93) 46(0.07) 1059 1031(0.97) 28(0.03)
VD 1 0 0 0 885 642(0.73) 243(0.27)
2 0 0 0 456 356(0.78) 100(0.22)
3 0 0 0 965 717(0.74) 248(0.26)
Clinical characteristics
Age 50.6 ± 0.4 51.2 ± 0.5 49.8 ± 0.5 60.3 ±0.2 59.8 ± 0.3 61.8 ± 0.54
BMI 29.0 ±0.2 27.97 ± 0.2 30.3 ± 0.3 28.9 ± 0.1 28.3 ± 0.1 31.0 ± 0.3
Total Chol 4.51 ± 0.02 4.42 ± 0.03 4.62 ± 0.03 4.48 ± 0.02 4.43 ±0.03 4.66 ± 0.05
HDL-Chol 1.26 ±0.01 1.18 ±0.03 1.33 ±0.01 1.15 ±0.01 1.15 ± 0.01 1.25 ± 0.02
LDL-Chol 2.76 ± 0.02 2.73 ± 0.03 2.80 ±0.03 2.71 ±0.02 2.68 ± 0.02 2.84 ±0.06
TG 1.52 ± 0.02 1.60 ± 0.03 1.44 ± 0.03 1.78 ± 0.02 1.78 ± 0.03 1.78 ± 0.05
Fasting glucose 6.87 ± 0.16 6.80 ± 0.23 6.92 ± 0.22 9.45 ± 0.31 9.27 ± 0.37 9.88 ± 0.56
BP 120/83 119/81 121/82 128/84 130/85 127/83
The table shows the important clinical features of the studied coronary artery disease patients versus angiographed controls, as well as the portion of disease
traits in these groups. The numbers in brackets give the proportions of the total (all) values. MI, myocardial infarction; T2DM, type 2 diabetes mellitus; VD, number
of diseased vessels; FH, family history of CAD; hChol, hypercholesterolaemia; lHDL, low high density lipoprotein; hTG, high triglycerides; hLDL, high low density
lipoprotein cholesterol; HTN, BP as mm HG, hypertension, BP, blood pressure. Lipid and glucose levels are given as mmol/L.
Al-Najai et al. BMC Cardiovascular Disorders 2013, 13:17 Page 3 of 12
http://www.biomedcentral.com/1471-2261/13/17with the regulations laid down by the King Faisal Special-
ist Hospital and Research Centre Ethics Committee in
compliance with the Helsinki Declaration (http://www.
wma.net/en/30publications/10policies/b3/index.html) and
all participants signed an informed consent.
Linkage analysis and screening for mutations
Five ml of peripheral blood was sampled in EDTA tubes
from each of the study individuals after obtaining their
written consent, and genomic DNA extracted from leuko-
cytes by the standard salt method using PUREGENE
DNA isolation kit (Qiagen Sciences, Germantown, MD,
USA). For the genome-wide scanning with the Affymetrix
Gene Chip 250 sty1 mapping array (Affymetrix Inc.,
Santa Clara, CA, USA), 250 ng of genomic DNA was
digested with the restriction endonuclease StyI, mixed
with Sty1 adaptors and ligated with T4 DNA ligase. The
mixture was added to four separate PCR reactions, am-
plified, pooled and purified to remove the unincorpo-
rated dNTPs. The PCR product was then fragmented,biotinylated, hybridized to the 250 sty1 array for 18 h,
washed, stained and scanned as recommended by the
manufacturer. SNP genotypes, linear chromosomal loca-
tions and marker ordering were accomplished using the
Affymetrix GeneChipW Genotyping Analysis Software
(GTYPE) Version 4.0. Multipoint parametric linkage ana-
lysis was performed using the GeneHunter Easy Linkage
analysis software 4.0 (Affymetrix, Inc., Santa Clara, CA,
USA) for estimating the LOD scores. The disease was as-
sumed to be an autosomal dominant trait with 100%
penetrance. Copy Number Analyzer for GeneChipW
(CNAG) Ver. 3.0 (Affymetrix, Inc., Santa Clara, CA, USA)
was employed to check the shared chromosomal regions
of homozygosity.
Sequencing of the gene
The linkage study was followed by sequencing exons
and intron-exon junctions of the AGT gene in the family
members and 200 individuals from the general pop-
ulation using the MegaBACE DNA analysis system
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the DNA was subjected to PCR by standard methods de-
scribed elsewhere. Five μl of PCR product were then
treated with 2 μl of ExoSAP-IT (USB Corporation,
Cleveland, Ohio, USA) at 37°C for 30 min to allow the
hydrolytic removal of excess primers and dNTPs by
Exonuclease 1 and Shrimp Alkaline phosphatase. The
enzymes were inactivated at 80°C for 15 min, and the
sequencing reaction was initiated by mixing 2 μl DNA,
1 μl of 5 μmol primer, 8 μl of DYEnmic ET Dye
Terminator (Amersham Biosciences, Buckinghamshire,
UK) and 9 μl of distilled water. The mixture was ther-
mally cycled 40x at 95°C for 20 sec, 50°C for 15 sec,
and 60°C for 1 min. Unincorporated dye-labelled termi-
nators were removed by gel-filtration through the
DyeEx 96 plate (Qiagen, GmbH, Hilden, Germany). The
eluent was vacuum-dried and dissolved in 10 μl of load-
ing solution (GE Healthcare UK Ltd, Little Chalfont,
Buckinghamshire UK) for sequencing. Data were ana-
lyzed for SNPs by Lasergene software (DNASTAR, Inc.
Madison, WI USA).
Association experiments
Once the SNPs of interest were identified, genotyping
was achieved by TaqMan chemistry using the Applied
Biosystems real-time Prism 7900HT Sequence Detection
System (ABI Inc. CA, USA). Primers and the TaqMan
fluorogenic probes bearing a suitable reporter dye on the
5’-end and a quencher dye on the 3’-end were designed
using the Primer Express software V2.0 (ABI Inc., Foster
City, CA, USA) and procured from Applied Biosystems
(ABI, Warrington, UK). One probe (for allele 1) was la-
beled with VIC dye and the other (for allele 2) with
FAM dye at the 5’-end, and serial dilutions were run to
determine the optimal working concentrations. For each
reaction, a 25 μl mixture was prepared by mixing 5 μl
containing 50 ng DNA, 12.5 μl of 2x Universal mix
(Eurogentec, Liege Science Park, Seraing Belgium),
1.25 μl of 20x probe assay mix and 6.25 μl DNase-free
distilled water. Three no-template controls were in-
cluded in each plate for normalization of emission sig-
nal. The thermal profile for amplification for the first
cycle occurred at 50°C for 2 min, and 95°C for 10 min,
followed by 40 cycles of 94°C for 15 sec, and 60 C
for 30 sec. The plates were then scanned for FRET
signal using the 7900HT sequence detection system and
data analyzed using SDS 2.0 software (ABI, Foster City,
CA, USA).
Statistical analysis
Comparison of genotypes and alleles between different
groups for continuous dependent variables was achieved
by Analysis of Variance (ANOVA) or Student’s test as
appropriate. Categorical variables were analyzed by Chi-Square test, and logistic regression analysis was used to
compute odds ratios and their 95% confidence intervals.
Multinomial logistic regression was carried out to access
the relationship of the SNPs with CAD in the presence
of the different disease traits, and Bonferroni tests were
carried out to correct for the effect of age on these
relationships. All of these statistical analyses were
performed using the SPSS software version 20 (SPSS
Inc., Chicago, USA). The haplo.stats package in the R
Statistical Computing software (http://www.r-project.
org/) was used to perform haplotype-based association
analysis (http://mayoresearch.mayo.edu/mayo/research/
schaid_lab/software.cfm). Odd ratios for haplotypes were
calculated using the baseline haplotype GGTGGGGT
as reference, and the Haplotype Score statistic for the
association of a haplotype with the binary trait calcu-
lated as in Schaid et al. (2002) [34] and Lake et al.,
(2003) [35]. Significance of association was deter-
mined between haplotypes and the case–control status -
a binomial trait denoting whether or not a patient had the
disease. Data are expressed as mean ± SEM and associa-




In the present study, we focused on the possibility that
the AGT gene confers risk for cardiovascular risk traits
in a fashion that may influence pathways to acquiring
CAD, following an initial study linking the gene to early
onset of CAD in heterozygous familial hypercholesterol-
aemia. Interrogation of our sequencing data in the family
members and 200 individuals from the general popula-
tion with the HapMap (Http://hapmap.org) and Perlegen
(http://genome.perlegen.com) databases led to the iden-
tification of several known and unfamiliar SNPs within
the coding as well as the 3’ and 5’ untranslated regions
of the AGT gene. This resulted in the selection of a total
of 8 SNPs as informative for further evaluation. Apart
from their frequencies in the study family and general
population, selection of these SNPs was also partly based
on available information on their impact on disease, to
allow comparison with other data in the literature.
Association of AGT polymorphism and cardiovascular
disease traits
The SNPs selected for the study included (1) rs2067853G
>A, (2) rs7079G > T, (3) rs1926723T > C (4) rs699G >A,
(5) rs4762G >A, (6) rs3789679G > A, (7) rs2148582 G >A
and (8) rs5051T > C, sequentially numbered by the order
of their chromosomal/genomic locations (Figure 1), and
further referred to by these numbers for easy readability.
Two of the SNPs (rs699 and rs4762 were missense muta-
tions, while the rest were either intronic or resided in the
Figure 1 Linkage disequilibrium structure of the eight studied
angiotensinogen SNPs. The SNPs are shown sequentially as they
appear on the chromosome (not to scale). D’ = coefficient of linkage
disequilibrium; r = regression coefficient of linkage disequilibrium.
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Suppl data 1). The analysis for HTN (3521 cases versus
1094 controls) demonstrated causative associations for six
of the studied variants with the disease. Thereby, both the
rs2067853 G [Odds ratio(95% Confidence Interval) = 1.15
(1.04 - 1.28); p = 0.007] and the recessive rs2067853 GG
[1.44(1.17 - 1.78); p = 0.001], rs7079 GG [1.49(1.20 - 1.85)
p < 0.0001], rs699 G [1.19(1.08 - 1.31); p < 0.0001], rs699
(AG +GG) [1.26(1.10 - 1.46); p = 0.001], the rs3789679 A
[1.51(1.14 - 1.99); p = 0.004], rs2148582 GG [1.31(1.11 -
1.55); p = 0.002] and rs5051 (TC + CC) [1.32(1.13 - 1.60);
p = 0.001] conferred risk for HTN (Table 2). Our data also
implicated three of these variants, the rs2067853 GG
[1.16(1.01 - 1.33); p = 0.042] as well as the rs699 G [1.13
(1.03 - 1.23); p = 0.007] and rs699 AG+GG [1.20(1.09 -
1.31); p < 0.0001] in MI, while two others, rs7079 GG
[1.15(1.00 - 1.33); p = 0.054] and rs5051 (TC + CC) [1.12
(1.00 - 1.25); p = 0.051] displayed borderline causative
properties. Furthermore, obesity was linked to both the
rs3789679 A allele [1.59(1.28 - 1.98); p < 0.0001] and
its combined GA+AA genotypes [1.57(1.24 - 2.00);
p < 0.0001] as well as the rs4762 G [1.19(1.03 - 1.37);
p = 0.019] (Table 2). Thus, these results point to common
AGT variants as causative for hypertension, myocardial in-
farction and obesity in our population. Apart from the
rs1926723T > C (p = 0.074) which was only very weakly
implicated in T2DM, none of the other studied variants
showed any definable relationship with this disease in the
general population. Besides, some differences were ob-
served in the distribution of the causative alleles bygender, whereby the rs699 G (p = 0,014), rs4762 G (p =
0.019) and rs5051 C (p = 0.04) were predominantly found
among the male, while the rs2148582 G (p = 0.061) and
rs1926723 T (p = 0.074) were weakly related to the female
gender. However these differences did not seem to have
any impact on the relationships of the gene variants
with disease.
Test for interactive gene-traits relationship on coronary
artery disease
In order to test the likelihood of gene interactions
with risk traits as an underlying cause for CAD in our
studied population, multinomial logistic regression was
performed to access the relationship of the SNPs with
CAD in the presence of the different disease traits
(Additional file 2: Suppl data 3–8). To begin with, apart
from the major traits themselves, myocardial infarction,
hypertension, type 2 diabetes mellitus and obesity, only
the rs7079 T appeared to retain its causative association
with CAD following the Bonferroni adjustment (Tables 3
and 4; Additional file 2: Suppl. data 9). Multinomial re-
gression analysis indicated that this association was also
retained in the presence of MI. The rs1926723 C was
similarly associated with CAD in the presence of MI,
while rs2148582A also became significantly associated in
presence of HTN (0.002) and T2DM (p = 0.019). On the
other hand, the rs3789679 A was protective against
CAD in presence of MI (p = 0.001), HTN (p = 0.002),
T2DM (p = 0.019). Thus, the results demonstrate that
the relationships of these variants are retained in indi-
viduals harbouring CAD, pointing to their independence
from the presence or absence of the later. Put together,
the impact of the AGT variants on CAD seemed to de-
pend on the prevailing disease condition.
Haplotype analysis
Haplotyping involving different combinations of the
eight studied SNPs was performed for the disease
traits, employing the most prevalent 8-mer sequence
GGTGGGGT (frequency = 0.338) as the baseline for
comparative analysis of their relationships. To begin
with, it was noteworthy that this baseline haplotype itself
conferred risk for HTN (χ2 = 7.02; p = 0.0081). As shown
in Table 5, its 7-mer derivatives, GGTGGGG (block
1–7; χ2 = 10.23; p = 0.0014) constructed from SNPs 1–7
as well as GTGGGGT (block 2–8; χ2 = 7.03; p = 0.008)
constructed from SNPs 2–8, were also significantly asso-
ciated with HTN. The trend in these associations trick-
led down to the shorter sequences with the highest level
of significance being exhibited by its 4-mer GGTG (χ2 =
13.23; p = 0.0003). Apart from the GGTGGGGT, a sec-
ond 8-mer GGCGGAGT (χ2 = 5.10; p = 0.024) also con-
stituted a risk for HTN, with its shorter derivatives
displaying similar trends. Its 4-mer derivative GAGT
Table 2 Association of the AGT gene variants with cardiovascular risk traits
Variant Allele/Genotype CON Cases O.R.(95%C.I.) P-value
Hypertension N = 1596 N = 3521
rs2067853G > A G 0.681 0.711 1.15(1.04-1.28) 0.007*
GG 0.870 0.906 1.44(1.17-1.78) 0.001**
rs7079G > T G 0.683 0.712 1.14(1.03-1.27) 0.012
GG 0.879 0.915 1.49(1.20-1.85) <0.0001**
rs699G > A G 0.560 0.602 1.19(1.08-1.31) <0.0001**
(p.M268T) GG 0.791 0.821 1.21(1.03-1.44) 0.024
AG + GG 0.328 0.383 1.26(1.10-1.46) 0.001**
rs3789679G > A
A 0.028 0.042 1.51(1.14-1.99) 0.004*
AA 0.005 0.012 2.70(1.07-6.83) 0.036
GA + AA 0.052 0.072 1.41(1.05-1.90) 0.022
rs2148582G > A
G 0.563 0.587 1.10(1.00-1.21) 0.051
GG 0.786 0.828 1.31(1.11-1.55) 0.002*
rs5051T > C
C 0.571 0.599 1.12(1.02-1.24) 0.02
TC + CC 0.800 0.843 1.32(1.13-1.60) 0.001**
Myocardial infarction N = 1584 N = 3033
rs2067853G > A GG 0.889 0.902 1.16(1.01-1.33) 0.042
rs7079G > T GG 0.898 0.911 1.15(1.00-1.33) 0.054
rs1926723T > C T 0.961 0.969 1.25(0.99-1.57) 0.063
rs699G > A
G 0.573 0.602 1.13(1.03-1.23) 0.007*
GG 0.803 0.820 1.20(1.00-1.25) 0.047
AG + GG 0.343 0.384 1.20(1.09-1.31) <0.0001**
rs5051T > C TC + CC 0.822 0.838 1.12(1.00-1.25) 0.051
Obesity N = 3342 N = 1721
rs4762G > A G 0.887 0.903 1.19(1.03-1.37) 0.019
(p.M207T) AG + GG 0.192 0.167 0.85(0.72-0.99) 0.040
rs3789679G > A
A 0.032 0.050 1.59(1.28-1.98) <0.0001**
AA 0.008 0.015 2.00(1.12-3.58) 0.019
GA + AA 0.056 0.085 1.57(1.24-2.00) <0.0001**
The table compares the AGT allele/genotype frequencies (as proportions), odd ratios (O.R.), 95% confidence levels (95% C. I.) and the significance levels of the
associations in hypertension, myocardial infarction and obesity versus their respective angiographed controls. The letter N represents the population size.
*P < 0.01, **P < 0.001 by χ2 test.
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13.77; p = 0.0002) exhibited the highest level of signifi-
cance (Table 5). Besides, two other 8-mer haplotypes
GGTAGGGT (χ2 = 9.87; p = 0.0017) and ATTGGGAC
(χ2 = 6.75; p = 0.009) were protective against acquiring
HTN (AGT Haplo Additional file 2: Suppl data). Simi-
larly, their shorter variants displayed identical properties
with, for example, the 5-mer TAGGG (block 3–7; χ2 =
12.70; p = 0.0004) showing the most significant charac-
teristics. Further in-depth analysis of these trends reveals
a number of interesting features. The most important of
these is the observation that the primary 8-mer haplo-
types displaying opposite characteristics differ only at
the fourth nucleotide position, involving the rs699G > A.
Tracking the shorter haplotypes down to the 3-mers(e. g. block 4–6; AGG versus GGA) indicates clearly that
G allele of this SNP is consistently associated with
causative effects, while its complementary A allele con-
sistently mediates protective actions, therefore position-
ing this SNP at the core of the genomic link to HTN.
Equally interesting changes were linked with nucleotides
at positions 5 (rs4762G > A) and 6 (rs3789679G > A), in-
dicating that the G allele was causative while the A allele
was protective, and therefore pointing to these loci as a
central component linking AGT with HTN.
The analysis for T2DM also produced two causative
8-mer haplotypes, GGTAGGAC (χ2 = 5.66; p = 0.017)
and ATTGAGAC (χ2 = 5.93; p = 0.015), as well as pro-
tective ATTAGGAC (χ2 = 4.40; p = 0.036). Similar trends
were observed that culminated inversely with the size of
Table 3 The relationship of the angiotensinogen variants with coronary artery disease adjusted for the presence of its
risk factors
Variable Estimate S. E t P-value 95%C.I
Lower Upper
Sex −0.100 0.009 −11.296 <0.0001*** −0.122 −0.086
MI 0.555 0.010 58.143 <0.0001*** 0.574 0.613
HTN 0.036 0.010 3.509 <0.0001*** 0.009 0.051
T2DM 0.087 0.009 9.732 <0.0001*** 0.063 0.100
OBS −0.022 0.009 −2.435 0.015 −0.037 −0.003
Age 0.003 0.000 8.079 <0.0001*** 0.002 0.003
FH <0.00001 0.011 0.998 0.998 −0.021 0.021
rs7079T −0.020 0.009 −2.163 0.031 −0.035 0.001
MI _Intercept 1.255 0.395 3.174 0.002* 0.480 2.030
MI * rs3789679A −0.104 0.032 −3.229 0.001** −0.168 −0.041
MI * rs1926723C 0.092 0.035 2.597 0.009 0.022 0.161
MI * rs7079G 0.027 0.012 2.345 0.019 0.004 0.050
HTN _Intercept 0.371 0.549 0.675 0.500 −0.706 1.447
HTN* rs2148582A 0.065 0.021 3.095 0.002* 0.024 0.107
HTN * rs3789679A −0.074 0.035 −2.099 0.036 −0.143 −0.005
T2DM_ Intercept −0.089 0.418 −0.212 0.832 −0.908 0.731
T2DM * rs2148582A 0.056 0.024 2.347 0.019 0.009 0.103
T2DM * rs3789679A −0.099 0.044 −2.241 0.025 −0.186 −0.012
Gender_ Intercept −0.342 0.487 −0.702 0.482 −1.298 0.613
Female * rs2148582A 0.103 0.030 3.405 0.001** 0.044 0.162
Male * rs2148582G 1.256 0.645 1.948 0.051 −0.008 2.520
The table displays the significant relationship of the angiotensinogen gene variants with coronary artery disease in presence of the various disease traits. Detailed
analyses for the individual traits are given in the Additional file 1: Supplementary data file. S.E., standard error; t, Standard t-test MI, myocardial infarction; HTN,
hypertension; T2DM, type 2 diabetes mellitus. OBS, obesity; FH, family history of coronary artery disease. *P < 0.01, **P < 0.0.001, ***P < 0.0001.
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ATTGAG (block 1–6; χ2 = 8.17; p = 0.004) was the most
conspicuous (AGT Haplo Additional file 2: Suppl data).
As in HTN, a couple of noticeable features could be
identified pointing to the rs699G > A and rs4762G > A as
distinguishing between causative and protective actions.Table 4 Adjustment for age in the association of AGT variant
Parameter Estimate S. E. t
A ≤44 * rs2148582A −0.694 0.341 −2.038
A ≤63 * rs5051C −0.075 0.036 −2.05
A ≤68 * rs5051C −0.119 0.04 −2.948
A ≤51 * rs3789679A −0.142 0.068 −2.068
A ≤63 * rs3789679A −0.138 0.064 −2.167
A ≤68 * rs4762A 0.081 0.038 2.16
A ≤51 * rs2067853A −0.065 0.031 −2.106
A ≤51 * rs7079G 0.066 0.025 2.687
The table shows the Bonferroni adjustments for the influence of age on the signific
data shows that the significance for association of the two variants rs5051C (for age
following Bonferroni correction. *P < 0.05, **P < 0.01, ***P < 0.005., age; S.E. standarFurthermore, obesity was linked with the 8-mer
GGCGGAGT (χ2 = 9.49; p = 0.0021), whereby its 5-mer
derivative GGAGT (block 4–8; χ2 = 10.96; p = 0.0009)
and the 3-mer GGA (block 4–6; χ2 = 15.94; p = 0.00005)
were the most significantly related (Table 5). Besides,





0.042* 0.168 −1.362 −0.026
0.04* 0.2 −0.146 −0.003
0.003*** 0.015 −0.197 −0.04
0.039* 0.195 −0.276 −0.007
0.03* 0.15 −0.263 −0.013
0.031* 0.155 0.008 0.155
0.035* 0.175 −0.126 −0.004
0.007** 0.035 0.018 0.114
ance of the relationship between the SNPs and coronary artery disease. The
s 63–68) and rs7079 (44–51) with coronary artery disease was retained
d error, t, standard t test C.I., confidence interval.
Table 5 Association of selected angiotensinogen
haplotypes with cardiovascular disease traits
SNP Block Haplotype Pooled Case Control χ2 P-value
Hypertension
1-8 GGTGGGGT 0.338 0.345 0.314 7.02 0.0081
1-7 GGTGGGG 0.355 0.365 0.327 10.23 0.0014*
2-8 GTGGGGT 0.339 0.347 0.316 7.03 0.008
1-5 GGTGG 0.408 0.417 0.381 8.97 0.0028*
4-8 GGAGT 0.022 0.025 0.013 11.48 0.0007**
4-7 GGAG 0.024 0.027 0.014 13.36 0.0003**
3-7 TGGGG 0.374 0.383 0.347 9.38 0.0022*
1-4 GGTG 0.465 0.475 0.431 13.23 0.0003**
5-8 GAGT 0.026 0.029 0.016 11.40 0.0007**
6-8 AGT 0.028 0.032 0.017 13.77 0.0002**
4-6 GGA 0.026 0.029 0.015 12.50 0.0004**
Myocardial Infarction
1-8 ATTGGGAC 0.057 0.061 0.048 6.68 0.010
1-7 ATTGGGA 0.060 0.065 0.049 8.89 0.0029*
2-8 TTGGGAC 0.059 0.065 0.049 8.68 0.0032*
1-6 ATTGGG 0.077 0.083 0.064 10.72 0.0011**
3-8 TGGGAC 0.094 0.101 0.080 10.71 0.0011*
2-7 TTGGGA 0.063 0.069 0.051 11.40 0.0007*
1-5 ATTGG 0.077 0.083 0.064 11.22 0.0008*
4-8 GGGAC 0.093 0.100 0.080 10.17 0.0014*
1-4 ATTG 0.093 0.101 0.077 13.92 0.0002*
2-6 TTGGG 0.084 0.090 0.073 8.05 0.0046*
2-5 TTGG 0.086 0.092 0.074 8.26 0.0041**
Obesity
1-7 GGCGGAG 0.015 0.021 0.012 10.08 0.0015**
2-8 GCGGAGT 0.014 0.019 0.011 9.22 0.0024**
1-6 GGCGGA 0.015 0.020 0.012 8.93 0.0028**
3-8 CGGAGT 0.014 0.019 0.011 8.73 0.0031**
4-8 GGAGT 0.022 0.029 0.018 10.96 0.0009**
3-7 CGGAG 0.015 0.020 0.012 9.03 0.0027**
5-8 GAGT 0.026 0.033 0.022 9.95 0.0016*
6-8 AGT 0.028 0.035 0.024 9.62 0.0019*
4-6 GGA 0.026 0.034 0.021 15.94 0.00005**
The most frequent 8-mer haplotype GGTGGGGT (0.338) was employed as the
baseline to determine the relative effects of the other haplotypes. Number 1
denotes rs2067853, 2 is rs7079, 3 is rs1926723, 4 is rs699, 5 is rs4762, 6 is
rs3789679, 7 is rs2148582 and 8 is rs5051 arranged sequentially by their
chromosomal positions, and blocks represent the range of variants
constituting the respective haplotypes. *P < 0.005, **P < 0.001 by χ2 test.
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and GGTGGGAT (χ2 = 4.25; p = 0.039), which exhibited
similar trends culminating in the 4-mer ATTG (χ2 =
13.92; p = 0.0002) being the most significantly involved.
Notably, in this population, the 8-mer ATTGGGAC
(χ2 = 6.68; p = 0.010) was associated in a causative fashionwith MI, while the ATTAGGAC (χ2 = 9.99; p = 0.0016)
was protective against the disease, properties which
were shared with T2DM (AGT Haplo Additional file 2:
Suppl data).
Most importantly, several haplotypes were shared
among the various risk traits. For example, the 5-mer
GGAGT posed risk for HTN (χ2 = 11.48; p = 0.0007),
obesity (χ2 = 10.96; p = 0.0009), while the 3-mer AGT
was also shared by HTN (χ2 = 13.77; p = 0.0002) and
obesity (χ2 = 9.62; p = 0.0019). The greatest similarities
were however found between T2DM and CAD/MI
which shared not only causative and protective 8-mer
haplotypes, but several other causative derivatives in-
cluding TGGGAC, TTGGGAC and ATTG, just to name
a few. Put together, several haplotypes, particularly
those encompassing the rs699G > A, rs4762G > A and
rs3789679G > A were shared among HTN, T2DM and
obesity as well as with CAD/MI in the present study.
The complete list of the haplotypes associated with each
disease trait is provided as supplementary data (AGT
Haplo Additional file 2: Suppl data).
Discussion
In the present study, we tested the likelihood of AGT
polymorphism interacting with important cardiovascular
risk traits, such as HTN, T2DM and obesity, contribut-
ing to disease pathways leading to atherosclerosis, fol-
lowing our previous finding of its linkage to early onset
of CAD in heterozygous familial hyperlipidaemia (un-
published results). Accordingly, we employed the eight
SNPs investigated in the early onset CAD study in the
same ethnically homogeneous, angiographed cohort of
native Saudi individuals, in which each subset of the
cardiovascular disease traits of interest was well-
documented. Our observations point to the different
AGT variants as invariably conferring risk for these traits
in our study population, whereby the most significant re-
lationships involved the HTN patient group. This disease
was linked to six of the eight studied SNPs (rs2067853,
rs7071, rs699, rs3789679, rs2148582 and rs5051) in a
causative fashion, unequivocally demonstrating the im-
pact of AGT polymorphism as a risk for acquiring HTN.
Of these variants, the rs699 (p.268 T) exhibited by far
the most significant relationship, in agreement with
several other studies that have implicated it in this
disease in other ethnic groups, including Caucasians
[36], Chinese[8], Slovaks[37], Polish[17] and Tunisians
[19], among others. Therefore, our study reaffirms its
place as a risk variant for HTN globally. However, current
literature does not seem to hold much data on the other
SNPs implicated in HTN in the present study. Therefore,
our observations with respect to their involvement in HTN
probably point to the novelty of their role as risk factors
for the disease, at least in native Saudis. On the other
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with HTN in the present study appears to be in conflict
with those reports implicating it in the disease [8-10].
Interestingly, rather than being involved in HTN, our
data indicates that the rs4762 is associated with obesity
and MI in the Saudi general population. To our know-
ledge, apart from a report suggesting an association of
the SNP with central obesity-related HTN in the Hong
Kong Chinese [8], literature seems to be also lacking
with respect to its potential role in metabolic disorders,
in general. Besides, we also observed some sharing of
causative properties for four of the variants by HTN and
CAD/MI as well as one (rs3789679) by HTN and obes-
ity, all of which similarly appear to be yet undocumented
in the literature. Thus, put together, our study identified
partly novel associations for various AGT variants con-
comitantly predisposing individuals to multiple cardio-
vascular disease traits, pointing to potential pleiotropic
activity of the AGT polymorphism on the risk of acquir-
ing atherosclerosis.
The primary question raised in this study was whether
or not the interactions of the AGT gene with these risk
traits might explain some of the disease pathways to ath-
erosclerosis. To begin with our data suggested that
although initially the studied SNPs appeared to be associ-
ated with CAD almost all association were abolished when
adjusted for age. On the other hand, the relationships of
the variants with the disease traits were retained in the
CAD population, pointing to these relationships as being
essentially independent of the presence or absence of
CAD. Notably, however, T2DM, which exhibited no
delineable relationship with any of the variants in the gen-
eral population, was weakly linked to three of the variants,
rs1926723, rs2148582 and rs5051, possibly suggestive of
the potential requirement for CAD presence in their inter-
actions with the disease. Furthermore, each disease subset
seemed to display unique variants that were linked to
CAD. However, some similarities between the T2DM and
HTN groups were observed in the associations of the vari-
ants with CAD, despite the above-mentioned lack of asso-
ciation with the former in the general population.
Moreover, different combinations of these traits also pro-
duced unique trends. Thereby, the rs699 and rs5051
appeared to be invariably implicated in the different traits.
These results imply therefore that the impact of the
changes in the AGT gene sequence on CAD may be partly
dependent on the type of disease trait involved.
The role of AGT polymorphism, particularly the rs699
and rs4762, in CAD has also been a subject of intense
research interest recently. In the present setting, while
the rs699 showed a strong link, the rs4762 exhibited
only borderline association with CAD. As is the case
with HTN, our findings concur with the reports of the
rs699 predisposing individuals to developing CAD/MI ina diversity of ethnic groups, including the Egyptian [13],
Japanese [16] and Spanish [21] populations. However,
the finding of a weak relationship for the rs4762 is not
in complete agreement with those linking it to CAD
[8,18,19,31]. Besides, both the p.207 T and p268T have
not only been implicated in CAD, but also in the severity
of atherosclerosis [24,25], requirement for coronary ar-
tery bypass surgery [38], and even as predictors of re-
stenosis recurrence after angioplasty [39,40], suggesting
a multi-faceted role for these two variants in CAD, as a
whole. Our data also provides some support for an asso-
ciation of the AGT polymorphism with the severity of
atherosclerosis, independently of other cardiovascular
risk traits, possibly strengthening the hypothesis of its
involvement in the extent of the disease reported else-
where [24,25]. Apart from these two, we also established
the sharing of four other variants by HTN and CAD.
Since alterations in blood pressure constitute a complex
risk trait for CAD, this sharing of causative variants by
CAD and HTN, its important predisposing disease, in
this and other ethnic populations seems to strongly im-
plicate gene-disease interactions in pathways leading to
CAD. A number of studies have produced evidence
pointing to the importance of gene-environment and
gene-disease interactions in complex diseases such as
CAD and its predisposing traits43-50. Thus, our findings
indeed furnish strong support for the notion of such
AGT interactions with the cardiovascular risk traits as a
triggering factor for CAD.
Nonetheless, it should be noted that various other
studies involving different ethnic populations, including
the Chinese [41,42], Indians [28] and Germans [43],
failed to establish any contribution of these variants to
the risk of CAD or HTN, possibly pointing to ethnic
variability in the practical relevance of these findings
globally. Several factors might be responsible for these
discrepancies. One of the most likely explanations is the
probability of inter-ethnical variation in the minor allele
frequencies among the various ethnic groups. Thus for
example, the frequency of the 268 T has been found to
vary significantly between black and white subjects in
some studies, leading to the suggestion of the 268TT
genotype as an independent risk for coronary events se-
lectively in black post-myocardial infarction patients
[30]. Besides, some studies have also implicated gender
and age in the association of these genetic changes with
disease. In the present study, gender appeared not to im-
pact the overall relationships for the different traits.
There was also no delineable confounding effect of fam-
ily history or smoking on the interactions of the AGT
gene with disease in our population.
The partial lack of consistency in some of our findings
on the individual variants with other previous observa-
tions raised our curiosity as to whether haplotyping
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interactions that may contribute to CAD pathways. To
begin with, as observed with the individual variants, by
far the greater majority of the haplotype constructs were
associated with HTN, in a much more significant fash-
ion than did the constituent variants themselves. In par-
ticular, it was noteworthy that the most common 8-mer
GGTGGGGT itself was implicated in HTN. Besides,
these associations culminated in the 5-mer or 4-mer de-
rivatives encompassing the three variants rs699G > A,
rs4762G > A and rs3789679G > A exhibiting the most
conspicuous relationships. Similar trends were also ob-
served for obesity, T2DM and MI, whereby each of the
traits was associated with a couple of the 8-mer haplo-
types and their shorter derivatives. Most importantly,
T2DM shared several causative haplotypes with CAD/
MI. Moreover, many other haplotypes were also com-
mon to two or more of the disorders, similarly pointing
to the presence of the rs699 and rs3789679 as the core
loci for these traits. Not only were the haplotypes more
significantly involved, but they also included causative
sequences common to the risk traits among themselves
and partly shared with CAD. Hence, while the associa-
tions of the individual variants with the disease traits do
not unequivocally delineate the indicators for their inter-
active involvement in atherosclerosis, haplotyping seems
to reveal several characteristics which may help decipher
such relationships. These observations indeed implicate
haplotypes as more reliable indicators for the involve-
ment of the AGT gene in the different diseases. Notably,
the involvement of haplotypes in the gene-environmental
interactions in CAD has also been highlighted recently,
with some studies describing events such a female sex-
related segregation with hypertension [32]. Therefore,
our findings support the notion of complex interactions
of such traits offering some basis for a mechanistic ex-
planation for the events leading to CAD. The putative
mechanisms involved in these interactions need however
to be addressed further to shed light on this complex
subject.
In this regard, it is noteworthy that three of the variants
investigated herein, which are also integral constituents
of the reported causative haplotypes, are non-coding
SNPs, residing either upstream in the promoter region or
downstream in the untranslated portion of the gene. This
raises the crucial question as to the nature of their role
on disease pathways. Some other AGT variants, in par-
ticular those residing in the promoter region of the gene,
have also been associated with disease, similarly raising
an interest in these sequences as key players in the mech-
anisms involved in its interactions with disease. Thus,
since only changes involving the two coding variants,
rs699 and rs4762, may be directly responsible for trigger-
ing alterations related to protein functional expressionassociated with disease, it can certainly be speculated that
the mechanisms involving alterations at such loci are not
directly ascribable to such changes in the AGT protein
functional expression. Hence, the findings of associations
for both coding and non-coding AGT variants with car-
diovascular disease traits implicate various mechanisms
possibly involving both protein functional changes and
gene regulatory processes in CAD pathways. The poten-
tial role of the 3’UTR in disease is increasingly gaining
acknowledgement, as it contains important elements, par-
ticularly the micro RNAs, regulating certain properties of
the gene, such as mRNA maturation. While not much
speculation can be derived from the current observations
alone, it seems nonetheless reasonable to argue that such
mechanisms might be related to gene regulatory pro-
cesses. The findings also provide a working basis for the
notion of the AGT 3’UTR-trait interactions as an import-
ant component of pathways leading to atherosclerosis.
This notion thus advocates for further studies on this
subject.
Conclusions
We therefore conclude that the AGT constitutes an inde-
pendent risk gene for HTN, obesity and MI, which may
be important in the manifestation of CAD associated
with these disorders. Together with the discovery of sev-
eral common causative haplotypes for these cardiovascu-
lar risk traits and CAD, these findings reaffirm the
potential pleiotropic role of the AGT on disease path-
ways leading to atherosclerosis, possibly involving gene-
disease interactive mechanisms.
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